For the quarter, Exelixis reported net product revenue from the sale of Cometriq, its only FDA-approved product to treat metastatic medullary thyroid cancer, of $4.3 million.
http://ift.tt/1dTIgP3
http://ift.tt/1dTIgP3
Healthcare Law News: News on Healthcare Law continually updated from thousands of sources monitored by the B Media Network.
No comments:
Post a Comment